Pancreatic Cancer Consortium Members
James L. Abbruzzese, M.D., F.A.C.P.
M. G. and Lillie A. Johnson Chair for Cancer Treatment and Research
Professor and Chairman, Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Dr. Abbruzzese is a member of a number of numerous scientific advisory boards including the external scientific advisory board for the University of Massachusetts, The Arizona Cancer Center, The University of Colorado, and The Lustgarten Foundation for Pancreatic Cancer Research. Dr. Abbruzzese has published over 350 peer-reviewed articles, numerous chapters and reviews. In 2004, he Co-Edited a book entitled Gastrointestinal Oncology, published by Oxford University Press. His research group has been awarded a SPORE in pancreatic cancer and U54 grant on angiogenesis. In 2001 Dr. Abbruzzese served as a Co-chair for the American Association for Cancer Research Program Committee and he was the Program Chairman for the ASCO Annual Meeting in 2007. He has recently served as a member of the AACR Board of Directors. He is a past member of the AACR Research Fellowships Committee, the ASCO Grant Awards and Nominating Committees, and currently serves on the newly constituted NCI Clinical Trials and Translational Research Advisory Committee. He is a Deputy Editor of Clinical Cancer Research, and member of several other editorial boards including past service for the Journal of Clinical Oncology. His scholarly interests center on clinical and translational research for pancreatic cancer.
Charles S. Fuchs, M.D., M.P.H.
Associate Professor of Medicine, Harvard Medical School
Director, Center for Gastrointestinal Cancer, Dana-Farber Cancer Institute
Dr. Fuchs splits his time between clinical care, clinical research, and laboratory-based activities. His epidemiologic research focuses on environmental and genetic risk factors for colorectal and pancreatic cancer, and his laboratory assesses biochemical markers of gastrointestinal cancer risk, understanding molecular predictors of patient prognosis in colorectal and pancreatic cancers and the discovery of novel targets for cancer therapy. As a medical oncologist, Dr. Fuchs focuses his work on the treatment of patients with GI cancers and conducts clinical trials assessing novel targeted therapies. He is a cadre member of GI Committee for Cancer and Leukemia Group B and is Director of Dana-Farber Harvard SPORE Grant in GI Cancers. He has over 240 publications in such journals as The New England Journal of Medicine, JAMA, Journal of Clinical Oncology, Cell, and Nature.
Ralph H. Hruban, M.D.
Professor of Pathology and Oncology
Director of the Sol Goldman Pancreatic Cancer Research Center
The Johns Hopkins University School of Medicine
Dr. Hruban received his Doctor of Medicine from Johns Hopkins University. He continued at Johns Hopkins for his residency training, spent one year as a Fellow at Memorial Sloan-Kettering Cancer Center in New York, and then returned to Johns Hopkins to join the Faculty in 1990. He established the National Familial Pancreas Tumor Registry in January 1994.
Dr. Hruban has written over 500 scientific papers, 80 book chapters and reviews, and three books. He is recognized by the Institute for Scientific Information as a Highly Cited Researcher and by Essential Science Indicators as the most highly cited pancreatic cancer scientist - designations given to the most highly influential scientists. In addition to his research efforts, he helped create the Johns Hopkins Pancreatic Cancer Web Page. Dr. Hruban has received a number of awards including the Arthur Purdy Stout Prize for significant career achievements in surgical pathology, the Young Investigator Award from the United States and Canadian Academy of Pathology, the PanCAN Medical Visionary Award, and five teaching awards from the Johns Hopkins School of Medicine. Dr. Hruban is a member of the Scientific Advisory Board of PanCAN, The Joseph C. Monastra Foundation and The Michael Rolfe Pancreatic Cancer Foundation, and the Director of Science for The Lustgarten Foundation.
Tyler Jacks, Ph.D.
David H. Koch Professor
Director, Koch Institute for Integrative Cancer Research
Investigator, Howard Hughes Medical Institute
Dr. Jacks received his Young Investigator Award from the General Cinemas Charitable Trust in 1992, the year that he joined the faculty in the Department of Biology and the Center for Cancer Research (CCR) at MIT. He was promoted to Associate Professor with tenure in 1997, full Professor in 2000, and KI Director in 2001. He was named an HHMI Assistant Investigator in 1994 and currently a full Investigator. He received the AACR Award for Outstanding Achievement in Cancer Research in 1997 the ASMBM Amgen Award in 1998 and the Paul Marks Prize for Cancer Research in 2005. For several years, his research has focused on the construction and characterization of mouse models of cancer. His current research remains centered on the use of gene targeting to create more powerful and accurate mouse models of human cancer and to explore the pathways regulated by cancer-associated genes. They have recently developed novel strategies for cell-specific activation of the K-ras, which has led to important new models of lung cancer. They are currently using this strategy with a variety of compound-mutant mice to improve the lung cancer model and to develop new models of cancer of the pancreas, colon, ovary, and breast, among others. These strains are being evaluated with cutting-edge tools in genetics, genomics and imaging, as well as with various chemotherapeutic agents.
David Kelsen, M.D.
Edward S. Gordon Chair in Medical Oncology
Chief, Gastrointestinal Oncology Service
Memorial Sloan-Kettering Cancer Center
Dr. Kelsen is incumbent of the Edward S Gordon Chair in Medical Oncology and Chief of The Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine at Weill Medical College of Cornell University, New York. Dr. Kelsen’s research focuses on developmental therapeutics and multimodality therapy of gastrointestinal malignancies. He has served on several national committees, including the Oncologic Drugs Advisory Committee of the Food and Drug Administration, and is past Chairman of Research Council at MSKCC. He has received peer reviewed grant support for his research from the National Institutes of Health, the National Cancer Institute, and the American Cancer Society, and is currently the Principal Investigator of an NCI 01 for the Early Therapeutics with Phase 2 Emphasis.
Scott Lowe, Ph.D.
Investigator, Howard Hughes Medical Institute
Deputy Director, Cancer Center, Cold Spring Harbor Laboratory
Dr. Lowe received a Bachelor of Science Degree from the University of Wisconsin-Madison where he worked for several years studying the molecular basis of hypercholesterolemia. He performed his graduate studies at the Massachusetts Institute of Technology under the supervision of Dr. H. Earl Ruley, and received his Ph.D. for research on the role of the p53 tumor suppressor in oncogenic transformation, apoptosis, and chemosensitivity. After a brief postdoctoral position in the MIT Center for Cancer Research with Drs. David Housman and Tyler Jacks, Dr. Lowe initiated independent research at Cold Spring Harbor Laboratory as a Cold Spring Harbor Laboratory Fellow and then a member of the faculty. Dr. Lowe's research has made important contributions to our understanding of the p53 tumor suppressor pathway, as well as the processes of multi-step carcinogenesis, cellular senescence, and tumor-cell drug resistance. Dr. Lowe's current research focuses on control of apoptosis and senescence by cancer genes, and on the molecular genetics of drug sensitivity and resistance in spontaneous tumors. Most recently, he has been integrating mouse models, genomics, and RNA interference for identifying and studying cancer genes in vivo. This work has been recognized by several awards, including a Sydney Kimmel Foundation Scholar Award, a Rita Allen Foundation Scholar Award, the AACR Outstanding Investigator Award, the AACR-NFCR Professorship in Basic Cancer Research, the Paul Marks Prize for Cancer Research, and the AAAS Fellow Award.
Robert J. Mayer. M.D.
Faculty Vice President for Academic Affairs, Dana-Farber Cancer Institute
Stephen B. Kay Family Professor of Medicine, Harvard Medical School
Dr. Mayer has directed the Institute's Medical Oncology Training Program since 1975 and is presently the Director of the Hematology/Oncology Fellowship Program of Dana-Farber/Partners CancerCare. Dr. Mayer's research interests focus on gastrointestinal cancer a subject about which he has published extensively. Dr. Mayer established the Center for Gastrointestinal Oncology at the Dana-Farber Cancer Institute and is the past Chair of the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, a cooperative group sponsored by the National Cancer Institute. He has served as an Associate Editor for the New England Journal of Medicine, is a past President of the American Society of Clinical Oncology and the Association of Subspecialty Professors and is a former member of the Executive Committee of the American Board of Internal Medicine. Dr. Mayer is a graduate of Williams College and the Harvard Medical School.
David McConkey, Ph.D.
Professor, Cancer Biology and Urology
Deputy Division Head for Research, Division of Surgery
Director of Urological Research
University of Texas M.D. Anderson Cancer Center
Dr. McConkey received his BA in Biochemistry and American History from Brown University and his PhD from the Karolinska Institute in Stockholm. His recent work has focused on translational cancer research and the mechanisms of action of experimental therapeutics, particularly inhibitors of the proteasome and the epidermal growth factor receptor (EGFR) and TNF-related apoptosis-inducing ligand (TRAIL). Dr. McConkey has published over 150 papers in peer-reviewed journals and is a Project Leader on two Specialized Programs of Research Excellence (SPORE) grants (in bladder and pancreatic cancer). Dr. McConkey is on the editorial boards of Clinical Cancer Research and the Journal of Biological Chemistry and serves as a regular member of peer review panels for NCI and the Damon-Runyon Cancer Research Foundation. He is a member of several professional organizations including the American Urological Association, the Society for Basic Urological Research, the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Society of Biochemistry and Molecular Biology, and he is co-chair for translational research in the genitourinary tumors subgroup of the Southwest Oncology Group.
Eileen O'Reilly, M.D.Associate Attending Physician, Memorial Sloan-Kettering Cancer Center
Associate Professor of Medicine, Weill Medical College of Cornell University
Dr. O’Reilly received her medical degree at Trinity College in Ireland, where she was born. She completed her residency training in Ireland and fellowship training at MSKCC and has been a faculty member in the GI Oncology service at MSKCC since that time. Dr. O’Reilly has pancreatic and biliary cancers as the major focus of her clinical and research activities. Research initiatives include integration of molecular-based therapies and novel therapeutics for the treatment of pancreas cancer along with development of adjvuant and neoadjuvant therapy. At a national level, Dr. O’Reilly is a member of CALGB’s GI core committee and also participates in RTOG and ACOSOG. Dr. O’Reilly’s insitutional administrative commitments include participation in MSKCC’s IRB, Research and Clinical Councils. Dr. O’Reilly is the current President of the MSKCC medical staff.
Bruce Stillman, Ph.D., F.R.S.
President, Cold Spring Harbor Laboratory
Dr. Stillman obtained a Bachelor of Science degree with honors at The University of Sydney and a Ph.D. from the John Curtin School of Medical Research at the Australian National University. He then moved to Cold Spring Harbor Laboratory as a Postdoctoral Fellow in 1979. Dr. Stillman has been Director of the Cancer Center at Cold Spring Harbor since 1992, a position he still holds. In 1994, he succeeded Nobel Laureate Dr. James D. Watson as Director of Cold Spring Harbor Laboratory was appointed President in 2003.
Dr. Stillman’s research focuses on how chromosomes are duplicated in cells, a process that ensures accurate inheritance of genetic material from one generation to the next. Dr. Stillman has received a number of honors including election as a Fellow of The Royal Society in 1993. Dr. Stillman is a member of the Medical Advisory Board of the Howard Hughes Medical Institute and advises a number of other research organizations, including the M.I.T. Cancer Center and the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia and is an advisor to two biotechnology companies, one in Sydney, Australia. He was chair of the Board of Scientific Councilors of the National Cancer Institute and former vice-chair of the National Cancer Policy Board. He currently serves on the Board of Scientific Advisors of the National Cancer Institute and as a member of the Board of Life Sciences of the US National Research Council.
Matthew Vander Heiden, M.D., Ph.D.
Assistant Professor, Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
The focus of Dr. Vander Heiden's laboratory is to understand cellular metabolism and how it is regulated to meet the biosynthetic needs of proliferating cells. The laboratory uses a combination of biochemistry, molecular biology and mouse models to study how metabolic pathways are altered to promote cancer with a goal of finding novel approaches to target metabolism and impact cancer therapy in the clinic. Dr. Vander Heiden received his M.D. and Ph. D degrees from the University of Chicago. He also completed clinical training in Internal Medicine and Medical Oncology at the Brigham and Women’s Hospital/Dana-Farber Cancer Institute prior to completing a post-doctoral fellowship at Harvard Medical School.
Bert Vogelstein, M.D.
Investigator, Howard Hughes Medical Institute
Director, Ludwig Center for Cancer Genetics & Therapeutics
Clayton Professor of Oncology & Pathology, Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medical Institutions
Dr. Vogelstein's work on the genetic basis of human tumors forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies of the future. According to the Institute for Scientific Information, he is the most influential scientist in the world. Dr. Vogelstein has received numerous national and international awards for his research and is a member of the American Academy of Arts and Sciences, the European Molecular Biology Organization, the American Philosophical Society, the Institute of Medicine, and the National Academy of Sciences.